Therapeutic bispecific antibodies: The selection of stable single-chain fragments to overcome engineering obstacles

IDrugs

Volumn 13, Issue 8, 2010, Pages 543-549

  Mabry, R ^a   Snavely, M ^b  

^a Freelance Scientific Consultant   (United States)

^b Freelance Scientific Consultant   (United States)

Author keywords

Antibody fragment; bispecific antibody; bsAb; mAb; scFv; single chain variable fragment; stability

Indexed keywords

BISPECIFIC ANTIBODY; CERTOLIZUMAB PEGOL; CYSTEINE; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; POLYPEPTIDE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANTIBODY SPECIFICITY; BINDING AFFINITY; BIOENGINEERING; CARBOXY TERMINAL SEQUENCE; CELL MATURATION; CIRCULAR DICHROISM; COMPLEMENTARITY DETERMINING REGION; DISULFIDE BOND; DRUG HALF LIFE; DRUG POTENCY; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; GLYCOSYLATION; HEAVY CHAIN; HUMAN; IMMUNE SYSTEM; IN VIVO STUDY; LIGHT CHAIN; MOLECULAR SIZE; NONHUMAN; PROTEIN ENGINEERING; REVIEW; SHELF LIFE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIBODIES, BISPECIFIC; DRUG STABILITY; HUMANS; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES;

EID: 77955342209     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (8)

1. Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, Man W, Peale F, Ross S, Wiesmann C, Fuh G: Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science (2009) 323(5921):1610-1614.
2. Demarest SJ, Glaser SM: Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr Opin Drug Discov Devel (2008) 11(5):675-687.
3. Famm K, Hansen L, Christ D, Winter G: Thermodynamically stable aggregation-resistant antibody domains through directed evolution. J Mol Biol (2008) 376(4):926-931.
4. Honegger A: Engineering antibodies for stability and efficient folding. Handb Exp Pharmacol (2008) (181):47-68.
5. Jung S, Honegger A, Plückthun A: Selection for improved protein stability by phage display. J Mol Biol (1999) 294(1): 163-180.
6. Mabry R, Gilbertson DG, Frank A, Vu T, Ardourel D, Ostrander C, Stevens B, Julien S, Franke S, Meengs B, Brody J et al: A dual-targeting PDGFR?/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo. mAbs (2010) 2(1):20-34.
7. Nelson AL, Reichert JM: Development trends for therapeutic antibody fragments. Nat Biotechnol (2009) 27(4):331-337.
8. Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, Bose S, McCarthy D, Zhu RR, Santora L, Davis-Taber R et al: Simultaneous targeting of multiple disease mediators by a dual-variabledomain immunoglobulin. Nat Biotechnol (2007) 25(11):1290-1297.